Core Viewpoint - Recently, Heng Rui Medicine (600276) signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. to license its SHR6508 project, which is currently in Phase III clinical trials for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing dialysis [1] Group 1: Licensing Agreement - The licensing agreement involves a payment of RMB 30 million as an upfront fee from Hansoh Pharmaceutical to Heng Rui Medicine [1] - Heng Rui Medicine is eligible to receive regulatory milestone payments and commercial milestone payments related to the inclusion of the licensed product in the national medical insurance directory, which can total up to RMB 190 million [1] - The company is entitled to a tiered sales commission based on quarterly net sales, with a maximum rate of 9% [1] Group 2: Product Details - SHR6508 is a novel calcium-sensing receptor allosteric modulator intended for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease requiring dialysis [1] - The mechanism of SHR6508 involves enhancing sensitivity to calcium ions, which reduces the secretion of parathyroid hormone (PTH) in patients with secondary hyperparathyroidism [1] Group 3: Related Parties - Hansoh Pharmaceutical and its subsidiary, Jiangsu Hengrui Pharmaceutical Group Co., Ltd., are considered related parties due to the control of the company's actual controller and chairman, Sun Piaoyang, by his spouse [1] - This transaction constitutes a related party transaction as per the listing rules [1]

Group 1 - The company Heng Rui Medicine (600276.SH) has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group Co., Ltd. to license its SHR6508 project [1] - SHR6508 is a novel calcium-sensing receptor allosteric modulator intended for the treatment of secondary hyperparathyroidism in adult patients undergoing hemodialysis, currently in Phase III clinical trials [1] - The company’s paricalcitol soft capsule product is expected to be approved for market launch by the National Medical Products Administration in November 2025 [1] Group 2 - Hansoh Pharmaceutical and its subsidiary, Jiangsu Hengrui Pharmaceutical Group Co., Ltd., are controlled by the spouse of the company's actual controller and chairman, Sun Piaoyang, making them related parties under listing rules [2] - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [2]

Core Viewpoint - Heng Rui Medicine has signed an exclusive licensing agreement with Hansoh Pharmaceutical Group to license its SHR6508 project, which is currently in Phase III clinical trials for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing dialysis [1][2]. Group 1: Licensing Agreement - The company has entered into an exclusive licensing agreement with Hansoh Pharmaceutical for the SHR6508 project [1]. - A commercialization service framework agreement has been signed between Chengdu Shengdi Pharmaceutical and Jiangsu Hengrui Pharmaceutical Group, allowing the latter to provide non-exclusive commercialization services for the company's paricalcitol soft capsule product [1]. Group 2: Product Details - SHR6508 is a novel calcium-sensing receptor allosteric modulator aimed at treating secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, currently undergoing Phase III clinical trials [1]. - Paricalcitol is a synthetic vitamin D analog that suppresses parathyroid hormone (PTH) secretion by binding to the vitamin D receptor, thereby lowering serum PTH levels [1]. - The paricalcitol soft capsule is expected to receive approval from the National Medical Products Administration for market launch in November 2025 [1]. Group 3: Company Background - Hansoh Pharmaceutical is a leading innovation-driven pharmaceutical company in China, focusing on major disease treatment areas such as oncology, anti-infection, central nervous system, metabolism, and autoimmune diseases [2].